Surrozen Presents Preliminary Results Of Phase 1a Study Of SZN-043 In Liver Cirrhosis Patients At EASL 2024
Portfolio Pulse from Benzinga Newsdesk
Surrozen presented preliminary results of its Phase 1a study of SZN-043 in liver cirrhosis patients at EASL 2024. The treatment was safe and well tolerated, showing evidence of target engagement and Wnt-pathway mediated effects. Enrollment is ongoing for the Phase 1b study in severe alcohol-associated hepatitis.
June 10, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surrozen's Phase 1a study of SZN-043 in liver cirrhosis patients showed promising results, indicating safety, tolerability, and target engagement. This positive outcome could boost investor confidence and impact the stock price favorably.
The positive preliminary results from the Phase 1a study of SZN-043, including safety and target engagement, are likely to boost investor confidence. The ongoing enrollment in the Phase 1b study further supports the potential for future success, making a short-term positive impact on SRZN's stock price likely.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100